Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

By sjmartinez • March 8, 2024

Strober B, Blauvelt A, Warren RB, Papp KA, Armstrong AW, Gordon KB, Morita A, Alexis AF, Lebwohl M, Foley P, Kisa RM, Colston E, Wang T, Banerjee S, Thaçi D. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024 Mar 7. doi: 10.1111/jdv.19925. Epub ahead of print. PMID: 38451052.

Tags: Dermatology, Publications

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. Three-Year[...]

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG. The 487-gene expression[...]

Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma Mimic

Shammas R, Gudino-Rosales S, Kneiber D, Sarantopoulos GP, Aung T. Facial Swelling in a Young Adult With Type 1 Diabetes: Morbihan Disease as a Scleroderma[...]